Future experiments will seek to address the reason for the reduced angiogenesis in vivo, by examining the tumorigenic properties of breast cancer cells expressing forms of Tks5 mutated to affect its binding to various effector proteins. This evidence concerns the gene SH3PXD2A and breast cancer.